Head & Neck CancerPhase 1/2NCT07341737
SL-28 for Advanced Solid Tumours
A Phase 1/2 study testing SL-28 in people with Head & Neck Cancer and Pancreas Carcinoma, run by Second Life Therapeutics at 3 sites in Australia.
Trial summary
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic
- What is being tested?
- SL-28
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 3 sitesAustralia
- Study dates
- 14 Aug 2026to 1 Mar 2027
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study
- Adult males and females ≥18 years of age at screening
- Life expectancy of at least 3 months
- Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced)
- Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular/biomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate
- Eligible tumor types include:
Show all 29Show fewer
- Head and neck squamous cell carcinoma
- Thoracic malignancies (small-cell lung cancer, non-small cell lung cancer, esophageal cancer)
- Gastrointestinal malignancies (gastric, liver, colorectal, pancreatic adenocarcinoma)
- Genitourinary malignancies (bladder, renal cell, prostate cancer)
- Gynecologic malignancies (ovarian, endometrial cancer)
- Breast cancer and melanoma
- Evaluable disease per RECIST v1.1
- ECOG performance status 0-1 (or up to 2 at PI discretion)
- Adequate organ function, defined as:
- Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for liver metastases or Gilbert's syndrome)
- AST, ALT, alkaline phosphatase ≤2.5 × ULN (≤5 × ULN if liver metastases, at PI discretion)
- Creatinine clearance ≥50 mL/min (Cockcroft-Gault) or eGFR ≥50 mL/min (CKD-EPI)
- Absolute neutrophil count ≥1,000/mm³
- Platelet count ≥100,000/mm³
- Hemoglobin ≥90 g/L without transfusion within 2 weeks
- Prothrombin time and aPTT ≤1.5 × ULN (or stable INR if on anticoagulation)
- Female patients:
- -Non-childbearing potential (surgically sterile or postmenopausal), or of childbearing potential with negative pregnancy tests and agreement to effective contraception through 90 days post-dose
- Male patients:
- Agreement not to donate sperm for 90 days post-dose
- Agreement to use adequate contraception as applicable
- Suitable venous access for blood sampling
- Willingness and ability to comply with study procedures and protocol requirements
Who cannot join
- Ongoing toxicities ≥ Grade 2 per NCI CTCAE v5.0 (except alopecia, fatigue, sensory neuropathy, or adequately treated endocrine deficiencies)
- NYHA Class III or IV heart disease, myocardial infarction within 6 months, unstable arrhythmia, or ischemia on ECG
- QTcF >470 ms (females) or >450 ms (males)
- Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
- Requirement for systemic corticosteroids or other immunosuppressive therapy that cannot be discontinued ≥14 days prior to dosing
- Prior therapies within restricted timeframes:
Show all 19Show fewer
- Immune checkpoint inhibitors or biologics within 28 days
- Antineoplastic therapies, surgery, radiotherapy, or radiopharmaceuticals within 21 days
- Unapproved investigational drugs within 5 half-lives
- Nitrosoureas or mitomycin C within 6 weeks
- Concurrent malignancy within 5 years, except specified low-risk cancers
- Pregnancy or breastfeeding
- Known HIV, hepatitis B (HBsAg positive), or hepatitis C infection
- Inability or unwillingness to comply with protocol procedures
- History of anaphylaxis or significant allergy interfering with participation
- Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, neurologic, psychiatric, or immunologic disease within 6 months
- Conditions affecting drug absorption, distribution, metabolism, or excretion
- Receipt of live vaccines within 28 days prior to screening
- Participation in another investigational study within 30 days prior to screening
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Australia3 sites, 3 recruiting
- Recruiting
The Southern Oncology Clinical Research Unit (SOCRU)
Adelaide, South Australia, 5042
Ganessan Kichenadasse, ganessan.kichenadasse@socru.org.au
- Not yet recruiting
John Flynn Private Hospital
Gold Coast, Queensland, 4224
David Martin, MD, 0755980964, dm.oncology@gmail.com
- Not yet recruiting
Liverpool Hospital
Sydney, New South Wales, 3170
Udit Nindra, Dr, +61287389744, Udit.Nindra@health.nsw.gov.au
About this study
Official title: A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.
Read the detailed description
This study aims to assess the anti-tumour activity, safety, and interactions of single-agent SL-28 as an anti-cancer treatment in patients with a diverse array of solid tumours.
Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with advanced solid tumor, including head and neck cancer, small-cell lung cancer, non-small cell lung cancer; mesothelioma; oesophageal cancer, gastric cancer, liver cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, prostate cancer, ovarian cancer, endometrial cancer, breast cancer or skin cancer (melanoma) that is locally advanced, metastatic or unable to be surgically removed. Patients will also be assessed by a study doctor to ensure that they are well enough to participate in the trial before they will be offered enrolment into the study.
Study details All participants who choose to enroll in this study will receive 12 weeks of SL-28 treatment, administered on a 5-days-on, 2-days-off schedule. The first group of participants to receive SL-28 will be monitored for 12 weeks before a second group may be administered a higher dose of SL-28. Up to three cohorts will be enrolled to determine the highest safe and effective dose that does not cause severe side effects in patients.
It is hoped this study will show that SL-28 is safe to deliver to patients with solid tumour cancers, and determine the highest dose of SL-28 that cancer patients can safely receive.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell)
- Being tested
- SL-28
- Medical subject headings
- Head and Neck Neoplasms, Pancreatic Neoplasms, Neoplasm Metastasis, Adenocarcinoma of Lung, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SL-28Biological
Doses administered: 3×10^7 cells/injection, once daily, 5 days per week, 12 weeks.
Mode of administration: intravenous push
SL-28Biological
Doses administered: 6×10^7 cells/injection, once daily, 5 days per week, 12 weeks.
Mode of administration: intravenous push
SL-28Biological
Doses administered: to-be-determeined-later Mode of administration: intravenous push
| Study group | Role | What they receive |
|---|---|---|
| SL-28 Low Dose | Experimental | Not described Receives: Biological: SL-28 |
| SL-28 Intermediate Dose | Experimental | Not described Receives: Biological: SL-28 |
| SL-28 High Dose | Experimental | Not described Receives: Biological: SL-28 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with treatment-emergent adverse events
Treatment-emergent adverse events will be assessed and graded by the investigator according to the CTCAE v5
Measured: 12 weeks
To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion.
Assessment of dose limiting toxicities assessed by the occurrence of treatment-emergent adverse events(TEAEs) graded by the Investigator per the National Cancer Institute Common Terminology Criteria forAdverse Events, version 5.0.
Measured: 12 weeks
Change from baseline in ECG QT interval
Electrocardiograms will be recorded using a 12-lead ECG machine, and the QT interval (milliseconds) will be evaluated and summarized as change from baseline.
Measured: 12 weeks
Change from baseline in vital signs
Vital signs including systolic blood pressure (mmHg) and diastolic blood pressure (mmHg)will be measured using standard clinical equipment and summarized as change from baseline.
Measured: 12 weeks
Change from baseline in vital signs
Vital signs: Heart rate (beats per minute) will be measured using standard clinical equipment and summarized as change from baseline.
Measured: 12 weeks
Change from baseline in vital signs
Vital signs: body temperature (°C) will be measured using standard clinical equipment and summarized as change from baseline.
Measured: 12 weeks
Number of participants with dose-limiting toxicities (DLTs)
Dose-limiting toxicities will be assessed during the DLT evaluation period as defined in the protocol.
Measured: 12 weeks
Secondary outcomes (3)
Objective Response Rate (ORR) per RECIST 1.1
Objective response rate will be defined as the proportion of participants achieving a complete response (CR) or partial response (PR) according to RECIST version 1.1, as assessed by CT or MRI imaging.
Measured: 12 weeks
Objective Response Rate (ORR) per iRECIST
Objective Response Rate (ORR) per iRECIST
Measured: 12 weeks
Disease Control Rate (DCR) per RECIST 1.1
Disease control rate will be defined as the proportion of participants achieving CR, PR, or stable disease (SD) according to RECIST version 1.1.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2026
- Study start14 Aug 2026
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Head & Neck CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- This is a Phase 1/2 open-label study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of SL-28, an allogeneic, non human leukocyte antigen (HLA)-matched, modified T -cell-based treatment for advanced and unresectable solid tumours. The study will be conducted in 4 parts: * Part 1: Phase 1a dose escalation as a 3+3 design, with a single dose on Day 1 followed by daily dosing from Day 8 * Part 2: Phase 1b dose expansion at the maximum tolerated dose (MTD) * Part 3: Phase 2a dose expansion in 3 tumour types * Part 4: Phase 2a dose expansion in the tumour type showing the highest efficacy to SL-28
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Second Life Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07341737
- Sponsor's protocol ID
- SL-28-FIH
- Status last verified
- Sep 2026
- First submitted
- 17 Nov 2025
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tetz V, Kardava K, Shulenbayev O, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. Partial response in a patient with skeletal and hepatic metastases following resected pancreatic cancer to the novel cell therapy SL-28: a case report. Front Oncol. 2025 Nov 19;15:1636989. doi: 10.3389/fonc.2025.1636989. eCollection 2025.
PubMed 41347084Tetz V, Kardava K, Shulenbayev O, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. Dramatic Clinical Response to a Novel Form of Cell Therapy SL-28 in a Patient with Prostate Cancer and Bone Metastasis: A Case Report. Immunotargets Ther. 2025 Oct 29;14:1201-1207. doi: 10.2147/ITT.S547989. eCollection 2025.
PubMed 41185720Tetz V, Tetz G. Novel prokaryotic system employing previously unknown nucleic acids-based receptors. Microb Cell Fact. 2022 Oct 4;21(1):202. doi: 10.1186/s12934-022-01923-0.
PubMed 36195904Tetz V, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. Regulating white blood cell activity through the novel Universal Receptive System. bioRxiv [Preprint]. 2025 Jan 20:2025.01.06.631232. doi: 10.1101/2025.01.06.631232.
PubMed 39896476Tetz G, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz V. Universal receptive system as a novel regulator of transcriptomic activity of Staphylococcus aureus. Microb Cell Fact. 2025 Jan 3;24(1):1. doi: 10.1186/s12934-024-02637-1.
PubMed 39754239Tetz V, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. The universal receptive system: a novel regulator of antimicrobial and anticancer compound production by white blood cells. J Leukoc Biol. 2025 Jun 4;117(6):qiaf085. doi: 10.1093/jleuko/qiaf085.
PubMed 40578310
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours
- ClinicalTrials.gov ID
- NCT07341737
- Acronym / sponsor ID
- SL-28-FIH
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell)
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Second Life TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- 14 Aug 2026 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Mar 2027 (estimated)
- First posted
- 14 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.
Detailed description
This study aims to assess the anti-tumour activity, safety, and interactions of single-agent SL-28 as an anti-cancer treatment in patients with a diverse array of solid tumours.
Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with advanced solid tumor, including head and neck cancer, small-cell lung cancer, non-small cell lung cancer; mesothelioma; oesophageal cancer, gastric cancer, liver cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, prostate cancer, ovarian cancer, endometrial cancer, breast cancer or skin cancer (melanoma) that is locally advanced, metastatic or unable to be surgically removed. Patients will also be assessed by a study doctor to ensure that they are well enough to participate in the trial before they will be offered enrolment into the study.
Study details All participants who choose to enroll in this study will receive 12 weeks of SL-28 treatment, administered on a 5-days-on, 2-days-off schedule. The first group of participants to receive SL-28 will be monitored for 12 weeks before a second group may be administered a higher dose of SL-28. Up to three cohorts will be enrolled to determine the highest safe and effective dose that does not cause severe side effects in patients.
It is hoped this study will show that SL-28 is safe to deliver to patients with solid tumour cancers, and determine the highest dose of SL-28 that cancer patients can safely receive.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- This is a Phase 1/2 open-label study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of SL-28, an allogeneic, non human leukocyte antigen (HLA)-matched, modified T -cell-based treatment for advanced and unresectable solid tumours. The study will be conducted in 4 parts: * Part 1: Phase 1a dose escalation as a 3+3 design, with a single dose on Day 1 followed by daily dosing from Day 8 * Part 2: Phase 1b dose expansion at the maximum tolerated dose (MTD) * Part 3: Phase 2a dose expansion in 3 tumour types * Part 4: Phase 2a dose expansion in the tumour type showing the highest efficacy to SL-28
| Arm | Type | Receives |
|---|---|---|
| SL-28 Low Dose | Experimental | Biological: SL-28 |
| SL-28 Intermediate Dose | Experimental | Biological: SL-28 |
| SL-28 High Dose | Experimental | Biological: SL-28 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (29 listed)
- Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study
- Adult males and females ≥18 years of age at screening
- Life expectancy of at least 3 months
- Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced)
- Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular/biomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate
Key exclusion criteria (19 listed)
- Ongoing toxicities ≥ Grade 2 per NCI CTCAE v5.0 (except alopecia, fatigue, sensory neuropathy, or adequately treated endocrine deficiencies)
- NYHA Class III or IV heart disease, myocardial infarction within 6 months, unstable arrhythmia, or ischemia on ECG
- QTcF >470 ms (females) or >450 ms (males)
- Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
- Requirement for systemic corticosteroids or other immunosuppressive therapy that cannot be discontinued ≥14 days prior to dosing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SL-28Doses administered: 3×10^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push | Biological | SL-28 Low Dose |
| SL-28Doses administered: 6×10^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push | Biological | SL-28 Intermediate Dose |
| SL-28Doses administered: to-be-determeined-later Mode of administration: intravenous push | Biological | SL-28 High Dose |
Primary outcome
Number of participants with treatment-emergent adverse events
Time frame: 12 weeks
Treatment-emergent adverse events will be assessed and graded by the investigator according to the CTCAE v5
To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion.
Time frame: 12 weeks
Assessment of dose limiting toxicities assessed by the occurrence of treatment-emergent adverse events(TEAEs) graded by the Investigator per the National Cancer Institute Common Terminology Criteria forAdverse Events, version 5.0.
Change from baseline in ECG QT interval
Time frame: 12 weeks
Electrocardiograms will be recorded using a 12-lead ECG machine, and the QT interval (milliseconds) will be evaluated and summarized as change from baseline.
Change from baseline in vital signs
Time frame: 12 weeks
Vital signs including systolic blood pressure (mmHg) and diastolic blood pressure (mmHg)will be measured using standard clinical equipment and summarized as change from baseline.
Change from baseline in vital signs
Time frame: 12 weeks
Vital signs: Heart rate (beats per minute) will be measured using standard clinical equipment and summarized as change from baseline.
Change from baseline in vital signs
Time frame: 12 weeks
Vital signs: body temperature (°C) will be measured using standard clinical equipment and summarized as change from baseline.
Number of participants with dose-limiting toxicities (DLTs)
Time frame: 12 weeks
Dose-limiting toxicities will be assessed during the DLT evaluation period as defined in the protocol.
3 secondary outcomes
Objective Response Rate (ORR) per RECIST 1.1
Time frame: 12 weeks
Objective Response Rate (ORR) per iRECIST
Time frame: 12 weeks
Disease Control Rate (DCR) per RECIST 1.1
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
- Background: PubMed 41347084Tetz V, Kardava K, Shulenbayev O, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. Partial response in a patient with skeletal and hepatic metastases following resected pancreatic cancer to the novel cell therapy SL-28: a case report. Front Oncol. 2025 Nov 19;15:1636989. doi: 10.3389/fonc.2025.1636989. eCollection 2025.
- Background: PubMed 41185720Tetz V, Kardava K, Shulenbayev O, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. Dramatic Clinical Response to a Novel Form of Cell Therapy SL-28 in a Patient with Prostate Cancer and Bone Metastasis: A Case Report. Immunotargets Ther. 2025 Oct 29;14:1201-1207. doi: 10.2147/ITT.S547989. eCollection 2025.
- Background: PubMed 36195904Tetz V, Tetz G. Novel prokaryotic system employing previously unknown nucleic acids-based receptors. Microb Cell Fact. 2022 Oct 4;21(1):202. doi: 10.1186/s12934-022-01923-0.
- Background: PubMed 39896476Tetz V, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. Regulating white blood cell activity through the novel Universal Receptive System. bioRxiv [Preprint]. 2025 Jan 20:2025.01.06.631232. doi: 10.1101/2025.01.06.631232.
- Background: PubMed 39754239Tetz G, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz V. Universal receptive system as a novel regulator of transcriptomic activity of Staphylococcus aureus. Microb Cell Fact. 2025 Jan 3;24(1):1. doi: 10.1186/s12934-024-02637-1.
- Background: PubMed 40578310Tetz V, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. The universal receptive system: a novel regulator of antimicrobial and anticancer compound production by white blood cells. J Leukoc Biol. 2025 Jun 4;117(6):qiaf085. doi: 10.1093/jleuko/qiaf085.
- Individual participant dataSharing planned: No
Related trials for Head & Neck Cancer
RecruitingPhase 2
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Esophageal Squamous Cell Carcinoma, Immunotherapy
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
RecruitingPhase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast Neoplasms, Colorectal Neoplasms
Active, not recruitingPhase 3
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing SL-28 in people with Head & Neck Cancer and Pancreas Carcinoma, run by Second Life Therapeutics at 3 sites in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 29 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact George Tetz, MD, PhD (16466173088, clinical@secondlifetx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with treatment-emergent adverse events (time frame: 12 weeks). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07341737, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.